ERA-NET: Aligning national/regional translational cancer research programmes and activities

TRANSCAN-2

Joint Transnational Call for Proposals 2017 (JTC 2017) on:
"Translational research on rare cancers"

Pre-proposal Application Form

1. Project title
(max 150 characters including spaces):

2. Project acronym (max. 10 characters):

3. Project duration (months):

4. Project coordinator (research partner 1 in the consortium):

Surname	
Name	
Country	
Position	
Institution/Department	
Address	
Phone + Fax	
E-mail address	
Type of entity (tick as appropriate)	☐ Academia (universities or other higher education or research institutions) ☐ Clinical or Public Health (hospitals/public health and/or other health care settings and health organisations) ☐ Small and Medium-sized enterprises (SME) or Industry

5. Other research partners

No.	Country	Surname of research partner (principal investigator)	Name of research partner (principal investigator)	Institution, department & full address	Phone & Fax	Email address	Type of entity		
							Academia	Clinical or Public Health	SME or Industry
2							☐	☐	☐
3							☐	☐	☐
4							☐	☐	☐

5							☐	☐	☐
6							☐	☐	☐
7							☐	☐	☐

8*							☐	☐	☐
9*							☐	☐	☐
10*							☐	☐	☐

”

11*							☐	☐	☐

* Lines 8,9,10 and 11 have to be filled only when the maximum number of 7 research groups is increased with partners from Estonia, Latvia, Slovakia andTurkey, up to a maximum of 4 additional partners from the 4 countries, to reach a maximum total of 11 research groups in a proposal (See Call text, section 4.1).

6. Total requested funding: € 0,00

7. Keywords (max 1000 characters including spaces)

Please indicate three to seven keywords by using the MeSH vocabulary representing: the scientific content [(type of cancer; specific aim(s) and topic(s) (see Call Text, chapter 2. Aim of the call)]; the methodological and technological approach(es).

8. Project abstract (max 3,000 characters including spaces, equivalent to about 3/4 of an A4 page)

The abstract should contain:

a. Background and rationale
b. Hypothesis
c. Aims (primary and secondary)
d. Methods
e. Expected results and potential impact

9. Adherence of the proposal to the scope, aims and specific topics of the call
(see Call Text, chapter 2. Aim of the call). Proposals addressing one single aim and one single bullet point within the chosen aim will be allowed. Please, select as appropriate.

Aim 1: Design and conduct of translational research studies exploiting/combining resources from current clinical trials, bio-repositories and epidemiology-type resources.

☐ - Translational studies based on the analysis of data and/or of clinically annotated specimens from previously conducted/ongoing trials with adequate follow up.

☐ - Conduct of studies for cancer risk assessment in rare cancers leveraging upon access to institutional and/or national cancer registries.

☐ - Identification and characterization of the etiopathogenetic determinants involved in rare cancers

Aim 2: Development and exploitation of translational research platforms (e.g., patient derived xenograft models/organoids/tissue collections) to study drug responses/resistance and toxicity, and perform drug screens or repurpose approved anticancer drugs.

☐ - Tissue collection, and genetic and epigenetic characterization of patient-derived rare tumor xenografts (PDXs).

☐ - Three-dimensional cultures (or 'organoids') obtained from patients' tumours which closely replicate key properties of the original cancers.

☐ - Other translational research platforms that give insights into the drug responses/resistance and toxicity of drugs, and help perform drug screening for the treatment of rare diseases.

AIM 3: Implementation of precision biomarkers for better stratification of the clinical cohorts.

☐ - Validation and implementation of rare cancers associated biomarkers as molecular predictors of therapeutic response, treatment resistance and disease outcome.

☐ - Use of innovative, high throughput technologies designed to facilitate the comprehensive ‘omic assessment of genomes, transcriptomes, proteomes, metabolomes, etc. of patients affected by rare cancers.

☐ - Design and conduct of phase I and/or phase II clinical studies aiming at the study of precision biomarkers (including approaches based on liquid biopsies to enable non-invasive assessment of tumour heterogeneity and to monitor tumour dynamics) in patients diagnosed with rare cancers.

Has the project been submitted elsewhere?

☐ Yes

☐ No

10. Project description

(maximum 20,000 characters including spaces, equivalent to about five A4 pages.

In this section blocks of text no longer than 4000 characters each have to be uploaded separately in each available page. Copy and paste non formatted texts.)

This part should contain:

- Description of the project rationale, in terms of medical need, and of the present state of the art in the field(s). Description of the envisioned solution for the medical need. Description of a summary of the relevant literature;
- Description of the project aims;
- Statement of the research hypothesis(es);
- Preliminary data;
- Description of the methods with specific regard to the study design, the study population(s), intervention/exposure, groups of comparison, and outcome of interest. Details are also needed regarding the study sample size as defined by *ad hoc* power calculations, and the strategic plan for statistical analysis;
- Novelty and originality of the project;
- Feasibility of the project: information about the experience of the research consortium partners in the field; management structure and related implementation plan; added value of the proposed transnational collaboration;
- Information about the potential impact on early detection and/or progression of rare cancers with reference to the development, dissemination and use of project results.

As annexes, it should contain:

- References (one page maximum, to be uploaded as a separate pdf file);
- Diagrams, working plan, project schedule (e.g. Gantt chart) and figures (in total three pages maximum, to be uploaded as a separate pdf file).;

”

11. Capacity building activities (if eligible for the funding organization / country) (maximum 2,000 characters including spaces, equivalent to about half of an A4 page).

Please specify whether the project will include capacity building activities. If so, please describe the nature and purpose of the planned activities taking into account information described in the section 2.2 of Call Text. The budget will have to be mentioned in the financial plan (sections 13 and 14) in the appropriate line.

12. Brief CV for each partner in the research consortium including a description of the main domain of research and a list of the five most relevant publications within the last five years regarding the proposal (maximum 4,000 characters including spaces equivalent to about one A4 page for each partner).
Coordinator

Partner 2

Partner 3

Partner 4

Partner 5

Partner 6

Partner 7

*Partner 8**

*Partner 9**

*Partner 10**

*Partner 11**

13. Global financial plan: sum of year 1-3. Please describe the <u>requested budget</u> only.
(Please note that eligibility of costs is subject to national/regional rules and regulations: refer to the Annex 4 of the "Call text").

Acronym:							
No.	Project coordinator	Partner 2	Partner 3	Partner 4	Partner 5	Partner 6	Partner 7
Name (principal investigator)							
Country							
Funding organisation							
Personnel (€) - Scientist - PhD-Student - Technician - Other							
Person months - Scientist - PhD-Student - Technician - Other							
Consumables (€)							
Equipment (€)							
Study/Clinical trial (€)[1]							

”

Travel (€)[2]							
Capacity building (€)[3]							
Other direct costs (€)[4]							
(National/regional) Overheads (€)							
Total requested budget (€)	€ 0,00	€ 0,00	€ 0,00	€ 0,00	€ 0,00	€ 0,00	€ 0,00

[1] If applicable: incl. clinical trial drugs/compounds, clinical trial fees and insurance.
[2] Travel expenses should include the participation of the coordinators and/or principal investigators in an intermediate and/or a final status symposium to present the results of their projects (organized by the Joint Call Secretariat).
[3] Separate budget for capacity building activities (if eligible for the funding organization/country).
[4] e.g. subcontracting, provisions, licensing fees.

Acronym:				
No.	Partner 8*	Partner 9*	Partner 10*	Partner 11*
Name (principal investigator)				
Country				
Funding organisation				
Personnel (€) - Scientist - PhD-Student - Technician - Other				
Person months - Scientist - PhD-Student - Technician - Other				
Consumables (€)				
Equipment (€)				
Study/Clinical trial (€)[1]				

Travel (€)[2]				
Capacity building (€)[3]				
Other direct costs (€)[4]				
(National/regional) Overheads (€)				
Total requested budget (€)	€ 0,00	€ 0,00	€ 0,00	€ 0,00

[1] If applicable: incl. clinical trial drugs/compounds, clinical trial fees and insurance.
[2] Travel expenses should include the participation of the coordinators and/or principal investigators in an intermediate and/or a final status symposium to present the results of their projects (organized by the Joint Call Secretariat).
[3] Separate budget for capacity building activities (if eligible for the funding organization/country).
[4] e.g. subcontracting, provisions, licensing fees.
*Columns 8, 9, 10 and 11 have to be filled only when the maximum number of 7 research group is increased with partners from Estonia, Latvia, Slovakia and Turkey, up to a maximum of 4 additional partners from the 4 countries, to reach a maximum total of 11 research groups in a proposal
(See call text, section 4.1)

Total Request Funding : € 0,00

14. Individual financial plan: sum of year 1-3.

(Please note that eligibility of costs is subject to national/regional rules and regulations: refer to the Annex 4 of the "Call Text")

14.1

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.2

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.3

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.4

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.5

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.6

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.7

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.8

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.9

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.10

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

14.11

Partner name:		
Funding organisation		
Country		
	Requested budget	Justification
Personnel (€)		
Consumables (€)		
Equipment (€)		
Study/Clinical trial (€)		
Travel (€)		
Capacity building (€)		
Other direct costs (€)		
(National/regional) Overheads (€)		
Total budget (€)	€ 0,00	

15.Reviewers

Please note that providing this information is optional. The Call teering Committee (CSC) will consider these provided suggestions in case they do not interfere with the objective and thorough evaluation of the proposal.

Suggested reviewers for reviewing this proposal (up to five), without a conflict of interest (i.e. not working in the same institute, no co-publication in the past 5 years).

Name	Institute	Email address

Reviewers to be excluded from reviewing this proposal (up to five)

Name	Institute	Email address

16. IF APPLICABLE

A signed **written confirmation that the project partner with own funding** (also from a country/ region not partecipating in the JTC 2017) has secured his/her funding has to be uploaded as a separate pdf file.

PLEASE NOTE

- **Proposals that do not meet the national/regional eligibility criteria and requirements will be declined without further review.**

USEFUL LINKS

http://www.transcanfp7.eu

Online submission will be possible from 5 December 2017
http://transcan.cbim.it